|1.||Kaiser, Christine: 1 article (04/2010)|
|2.||Azorsa, David O: 1 article (04/2010)|
|3.||Meurice, Nathalie: 1 article (04/2010)|
|4.||Arora, Shilpi: 1 article (04/2010)|
|5.||Beaudry, Christian: 1 article (04/2010)|
|6.||Gonzales, Irma M: 1 article (04/2010)|
|7.||Bisanz, Kristen M: 1 article (04/2010)|
|8.||Robeson, Alexander C: 1 article (04/2010)|
|9.||Petit, Joachim: 1 article (04/2010)|
|10.||Stockwell, Brent R: 1 article (11/2004)|
|1.||Tuberous Sclerosis (Bourneville's Disease)
11/16/2004 - "We performed a small synthetic lethal screen and identified a compound (macbecin II) that has reduced activity in cells with RNA interference-mediated decrease in the expression of tuberous sclerosis 2. Thus, we have developed a microarray-based screening system for testing the effects of small molecules on mammalian cells by using an imaging-based readout. "
|2.||Colonic Neoplasms (Colon Cancer)
04/01/2010 - "Our results demonstrate that Macbecin II is specifically active in colon cancer cells having a SMAD4-negative background and thus is a potential candidate for further investigation in a drug discovery perspective."
04/01/2010 - "Chemogenomic analysis identifies Macbecin II as a compound specific for SMAD4-negative colon cancer cells."